Essity Pays 284 Million Dollars for Kenvue's Brazil Feminine Care Business in Latest Consolidation Play

Swedish hygiene giant Essity AB announced on Tuesday it has agreed to acquire Kenvue's feminine care business in Brazil for $284 million, marking the company's second major acquisition in the category this year and signaling that the global feminine care market is in the middle of a consolidation wave.

The transaction, structured as a cash-and-debt-free asset purchase, includes ownership of the Carefree, Sempre Livre, and o.b. brands for sanitary pads, liners, and tampons, along with related manufacturing equipment in Brazil. The deal is expected to close in the fourth quarter of 2026, pending regulatory approvals.

For Essity, the acquisition is a strategic bet on Brazil's growing feminine care market and a continuation of its push to expand in what CEO Ulrika Kolsrud called "higher-value categories." For Kenvue — the consumer health spinoff from Johnson & Johnson — the sale is a streamlining move that allows the company to focus on its core oral care, skin care, and over-the-counter medication businesses.

A Market Leader Doubles Down on Brazil

Essity is no stranger to the Brazilian market. The Stockholm-based company already operates a significant presence in the country through brands like Tork, Tena, and Libresse, and it has been methodically building out its feminine care portfolio in Latin America for years.

The Kenvue acquisition gives Essity immediate access to three well-established brands that generated approximately 800 million Brazilian reais (roughly 1.4 billion Swedish kronor) in net sales over the 12-month period ending June 30, 2026. Essity described the acquired business as having "good profitability," though it did not disclose specific margin figures.

"The acquisition strengthens the company's position in Brazil's feminine care market," CEO Kolsrud said in a statement, "representing another step in its strategy to expand in its higher-value categories."

Brazil is the largest consumer market in Latin America, with a population of more than 200 million and a rapidly growing middle class. The country's feminine care market has been expanding steadily, driven by rising incomes, increased awareness of menstrual health, and a shift toward premium and sustainable products. For Essity, the Kenvue deal is a shortcut to market share in a category where building brand loyalty from scratch can take decades.

The Second Big Feminine Care Deal This Year

The Kenvue acquisition is Essity's second major move in the feminine care space in 2026. In February, the company acquired Edgewell Personal Care's North American feminine care brands, including Stayfree, Carefree, and o.b., in a deal that gave Essity a commanding position in the U.S. market.

The back-to-back acquisitions suggest Essity is executing a deliberate global strategy: buy established brands in major markets, integrate them into its existing distribution network, and leverage economies of scale to drive profitability. It's a playbook the company has used successfully in other categories like tissue and incontinence care, and it's now applying that same approach to feminine care.

Industry analysts say the strategy makes sense. The global feminine care market is fragmented, with dozens of regional players competing alongside a handful of multinational giants like Procter & Gamble, Kimberly-Clark, and Unicharm. Consolidation allows companies like Essity to gain pricing power, reduce overhead, and invest more heavily in innovation and sustainability — areas where consumers are increasingly demanding progress.

What the Deal Means for Kenvue

For Kenvue, the sale of its Brazilian feminine care business is part of a broader portfolio rationalization. The company, which spun off from Johnson & Johnson in May 2023, has been under pressure from investors to streamline its operations and focus on categories where it has clear leadership positions.

Kenvue's core brands include Listerine, Aveeno, Neutrogena, and Tylenol — household names with strong consumer loyalty and pricing power. Feminine care, while profitable, was a smaller and more competitive piece of the portfolio, particularly in markets like Brazil where Essity and other local players have stronger distribution networks.

By exiting the category in Brazil, Kenvue can redirect capital and management attention to its higher-margin businesses. The $284 million in proceeds will likely be used to pay down debt, fund share buybacks, or invest in new product development in categories where the company has more competitive advantages.

Kenvue has not announced whether it plans to divest its feminine care operations in other markets, but the Brazil sale could be a signal that the company is open to further portfolio pruning if the right buyer comes along.

The Legal and Regulatory Process

The transaction is subject to customary regulatory approvals in Brazil, including antitrust clearance from the country's Administrative Council for Economic Defense (CADE). Given the size of the deal and the fact that Essity is already a major player in the Brazilian hygiene market, regulators will likely scrutinize the acquisition to ensure it doesn't reduce competition or harm consumers.

However, industry observers expect the deal to be approved without major conditions. The feminine care market in Brazil remains competitive even after the acquisition, with global brands like Always (Procter & Gamble) and local players continuing to offer consumers a wide range of choices.

Sullivan & Cromwell LLP advised Essity on the transaction, according to a statement from the law firm. Financial advisors were not disclosed.

What's Next for Essity's Feminine Care Strategy

With two major acquisitions in 2026 alone, Essity has signaled that feminine care is a strategic priority. The company now has a strong presence in North America, Latin America, and Europe, and it's likely eyeing further expansion in Asia and Africa — markets where feminine care penetration is still relatively low but growing rapidly.

Essity is also investing heavily in sustainability, an area where consumers are increasingly demanding action. The company has committed to making all its products recyclable or compostable by 2030, and it's developing plant-based and biodegradable alternatives to traditional plastic-based feminine care products.

For Kenvue, the question is what comes next. The company has now exited feminine care in Brazil, but it still operates in the category in other markets. Investors will be watching to see whether this is a one-off divestiture or the first step in a broader strategic shift.

Either way, the 284-million-dollar deal is a reminder that in the consumer goods industry, scale matters — and companies that can't compete globally are increasingly finding themselves on the selling side of the table.